All News #Library
Biotech
Rege Nephro acquires Tamibarotene assets from Syros Pharma.
15 Apr 2025 //
PR NEWSWIRE
Syros flunks phase 3 blood cancer trial, triggering loan default
14 Nov 2024 //
FIERCE BIOTECH
Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS
12 Nov 2024 //
BUSINESSWIRE
Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene
08 Jan 2024 //
BUSINESSWIRE
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
06 Dec 2023 //
BUSINESSWIRE
Syros Receives Fast Track Designation from the FDA for Tamibarotene
26 Jan 2023 //
BUSINESSWIRE

Market Place
Sourcing Support